Novo Nordisk has agreed to buy Akero Therapeutics and its drug candidate for metabolic dysfunction-associated steatohepatitis (MASH) for $4.7 billion upfront, shortly after claiming FDA approval to ...
Screenshot of PathAI's AIM-MASH AI Assist in action. An artificial intelligence model developed by PathAI – used to help diagnose metabolic dysfunction associated steatohepatitis (MASH) from liver ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback